Global Institute of Stem Cell Therapy and Research (GIOSTAR) announced today that about the conduction of the clinical trials for type 2 diabetes treatment based through stem cell therapy. These clinical trials on their way of processing to get approval by the Food and Drug Administration (FDA).
Dr. Anand Srivastava, who is the chairman and founding father of GIOSTAR led these trails. A team of scientists is involved in investigating the innovative approaches to manage the disease that is achieved through stem cell differentiation into insulin-secreting cells.
GIOSTAR is the pioneer of regenerative medicine. It is the leading company in this field. The San Diego based institute has spent more than two decades in the groundbreaking research of stem cell science under the leadership of Dr. Srivastava
It is a rough estimation that out of 10 Americans one is suffering from diabetes. Almost more 200,000 cases are reported in which mostly are under 20 years old. Many factors predispose people to diabetes such as a sedentary lifestyle that does not involve a single physical activity, excessive use of alcohol, high intake of high caloric food, and other unhealthy activities.
The incidence rate of this disorder increases which ultimately increases the cost of the patient’s care in the last years. American association of diabetes gives a rough estimation that in 2017 the patient care cost reaches $327 billion representing the direct medical costs and reduce productivity.
The words of Dr. Srivastava that in the past the conventional approach used to combat the disease is the pharmaceutical products. This approach usually involves many limitations. An alternative approach may provide by the GIOSTAR’s research team into the stem for addressing the disease concerns.
By using the drug, the adverse symptoms seen in the patients. On the other hand, the symptoms of post-procedure of stem cell therapy are limited to such an extent that it only causes nausea, headache, and mild fever.
National Institute of Health (NIH) listed more than 150 clinical trials on its website. All these trails show positive outcomes for the treatment of diabetes through the implementation of stem cell therapy.
This would be confirmed through the A1c (HbA1c), which shows the reduction in the values of blood glucose after having stem cell therapy. Moreover, the patients showed improved sensitivity for insulin after treatment. during the follow up of serval months, it is observed that patients still enjoy the benefit of the treatment.
The studies of Dr. Srivastava mainly focus on the therapeutic effect of mesenchymal stem cells (MSCs). These cells are isolated from the fat tissues of any viscera of adults. Mesenchymal stem cells involved in improving the pancreatic function, decrease systemic oxidative stress, prevent cell death and reduce insulin resistance by the secretion of various paracrine factors.
It was also observed that exposure to interferon-gamma and pro-inflammatory cytokines, MSCs become the source of anti-inflammatory cytokines. It may synthesize new cells that produce insulin.
The regeneration of beta is a cell of islets of the pancreas is noted when the patients are given infusions of stem cell therapy.
By decreasing the systemic inflammation, it promotes the sensitivity of insulin which is the main cause of insulin resistance. The conclusion given by Dr. Srivastava is that stem cell therapy is an alternative treatment for type 2 diabetes that may show long-lasting therapeutic effects.